Related Experiment Video

Updated: Aug 10, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Prednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitis

T Moshang1

  • 1University of Pennsylvania, Children's Hospital of Philadelphia, USA.

Cutis
|August 2, 2001
PubMed

Insights

Prednicarbate emollient cream 0.1% effectively treated pediatric atopic dermatitis over three weeks. The study found this nonhalogenated corticosteroid safe and well-tolerated, with no observed systemic effects or HPA axis suppression.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Background:

  • Atopic dermatitis is a common, chronic inflammatory skin condition in children.
  • Current treatments include emollients and topical corticosteroids.

Purpose of the Study:

  • To evaluate the safety and efficacy of prednicarbate emollient cream 0.1% for pediatric atopic dermatitis.
  • To assess potential systemic effects, including hypothalamic-pituitary-adrenal (HPA) axis suppression.

Main Methods:

  • A 3-week, open-label, multicenter study.
  • 55 pediatric patients (4 months to 12 years) with atopic dermatitis were enrolled.
  • Evaluated serum cortisol levels via cosyntropin stimulation test on days 1 and 22.

Main Results:

  • Prednicarbate emollient cream 0.1% showed significant improvements in atopic dermatitis.
  • No evidence of HPA axis suppression was detected.
  • Adverse events were minimal and within expected ranges for topical corticosteroids.

Conclusions:

  • Prednicarbate emollient cream 0.1% is a safe and effective treatment for pediatric atopic dermatitis.
  • Short-term (3-week) use demonstrated a favorable safety profile.
  • Further research may explore longer-term efficacy and safety.

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...